Supriya Lifescience Ltd
Supriya Lifescience Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹206Cr
- Net profit
- ₹29Cr
- Margin
- 22%
Guidance rank: #28 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Supriya Lifescience Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9). Q2 FY27 EBITDA: INR 454.0 Mn, representing a 37.5% YoY increase.
From Supriya Lifescience Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Supriya Lifescience's revenue grow in the September 2026 quarter?
- Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9).
- H1 FY27 revenue from operations: INR 3,960.4 Mn, a 14.8% YoY increase from INR 3,449.1 Mn in H1 FY26 (Page 7).
- Regional performance highlights Q2 FY27 revenue growth: Asia 37%, Europe 35%, LATAM 20%, North America 3%, Others 3% (Page 5).
2 more points from Supriya Lifescience Ltd's call on revenue
Create a free account to keep reading this call
What happened to Supriya Lifescience's margins in Q2 FY27?
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
What capex is Supriya Lifescience planning?
- New vitamin product block successfully commissioned.
- Civil work initiated for debottlenecking across all production blocks for capacity enhancement.
- Addition of a new F block planned.
- Five finished dosage manufacturing lines operational.
- Capacity expansion planned with addition of a new production block at Lote.
2 more points from Supriya Lifescience Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Supriya Lifescience raising money or cutting debt?
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Supriya Lifescience's order book?
2 more points from Supriya Lifescience Ltd's call on order book
Create a free account to keep reading this call
Supriya Lifescience Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Supriya Lifescience Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 206 |
| Operating profit (EBITDA) | 45 |
| Operating margin | 22% |
| Profit before tax | 38 |
| Net profit (PAT) | 29 |
| EPS (₹) | 3.63 |
Source: Supriya Lifescience Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹190 Cr, net profit ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Ipca Laboratories (Q2 FY27)
Volume-led growth in pain segment is around 8-9%, with price growth at 4-4.5%. Key concall takeaways from Ipca Laboratories Ltd's Q2 FY27 earnings call — and…
- Gland Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5). Key investor presentation takeaways from Gland Ph
- OneSource Specialty Pharma (Q2 FY27)
. Key concall takeaways from OneSource Specialty Pharma Ltd's Q2 FY27 earnings call — and how it ranks against sector peers.
- Sai Life Sciences Ltd (Q2 FY27)
Revenue for Q2 FY27: ₹659 Cr, a 23% year-on-year (YoY) growth from ₹537 Cr in Q2 FY26 (Page 8, 30). Key investor presentation takeaways from Sai Life Sciences L
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Supriya Lifescience Ltd Q2 FY27 results?
Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9). Q2 FY27 EBITDA: INR 454.0 Mn, representing a 37.5% YoY increase.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹6,999 Cr. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
New vitamin product block successfully commissioned.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.